Journal article
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
- Abstract:
-
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle. Thirty-five patients were treated. The MTDs w...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Investigational new drugs
- Volume:
- 31
- Issue:
- 2
- Pages:
- 370-380
- Publication date:
- 2013-04-01
- DOI:
- EISSN:
-
1573-0646
- ISSN:
-
0167-6997
- Source identifiers:
-
396409
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:396409
- UUID:
-
uuid:4bdd8218-f1a3-497a-a333-d7f60cdf3106
- Local pid:
- pubs:396409
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2013
If you are the owner of this record, you can report an update to it here: Report update to this record